EUVIMEDEUVIMED entdecken
VergleichsstudieRandomisierte kontrollierte StudieStudienprotokollOpen Access · CC BY 4.0

The PART randomised trial protocol: Partial Ablation versus Radical Treatment for prostate cancer

Richard J Bryant iD, Tom Leslie iD, Marc Laniado iD, Abhishek Sharma iD, Alistair Grey, John Withington iD, Christopher Blick, Edward Streeter, Sanjeev Kotwal, Oliver Hulson iD, William Cross, Daniel W Good und 31 weitere

BJU International · 2026-12 · 138 (6) · 1013-1024

DOI: 10.1111/bju.70448 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift BJU International, online erschienen am 18.09.2026. Verfasst von Richard J Bryant und 42 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. Hauptthemen laut MEDLINE: Prostatectomy, Prostatic Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Technology Assessment Programme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Primary objective: to determine whether prostate gland partial ablation (PA) has non‐inferior oncological treatment success vs radical treatment (RT) of localised intermediate‐risk prostate cancer (irPCa). Secondary objectives: to compare (i) participant‐reported urinary and sexual dysfunction side effects, (ii) short/medium term serious adverse events, (iii) health‐related quality of life (HRQoL), (iv) cost‐effectiveness; and to report (v) the need for repeat PA, (vi) accuracy of magnetic resonance imaging and biopsy protocols in determining suitability for PA, (vii) disease progression, local spread and metastases, (viii) medium‐term disease‐specific and overall mortality. Participants and Methods The ‘Partial prostate Ablation versus Radical Treatment’ (PART; International Standard Randomised Controlled Trial Number ISRCTN17249875) is a UK‐wide, multicentre, pragmatic, randomised controlled trial investigating whether PA (high‐intensity focused ultrasound [HIFU] or irreversible electroporation [IRE]) is non‐inferior to RT (radical prostatectomy, radical radiotherapy, or low‐dose‐rate brachytherapy [LDR‐B]) in treating localised irPCa. A Qualitative Research Integrated within Trials (QuinteT) Recruitment Intervention is included to optimise recruitment and informed consent. Primary outcome treatment success for PA will be determined by prostate biopsies and imaging, and for RT using standard definitions. Participants will receive treatment according to their randomised allocation, with HIFU or IRE for PA depending on lesion location, and radical prostatectomy, radical radiotherapy, or LDR‐B according to patient and physician preference for RT. Based on 95% and 85% oncological treatment success for RT and PA, respectively, with a non‐inferiority margin of 20%, at median 3 years of follow‐up, PART requires 275 recruited men (137 per group, randomised on a 1:1 basis), for 80% power, with a one‐sided alpha of 0.025. Allowing for a 10% total withdrawal or dropout rate, PART requires 306 recruited and randomised participants.

Conclusions

The PART trial will provide robust prospective data and high‐level randomised evidence to determine oncological treatment effectiveness of PA vs RT for localised irPCa, along with comparative side effect, HRQoL, and health economics evaluations, to inform clinical decision‐making.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProstatectomyProstatic NeoplasmsHumansMaleBrachytherapyIrreversible Electroporation TherapyQuality of LifeTreatment OutcomeMulticenter Studies as TopicPragmatic Clinical Trials as Topic

Stichwörter der Autor:innen

biopsybrachytherapyclinical endpointmedicineprostateprostate brachytherapyprostate cancerprostatectomyquality of liferandomised controlled trial

Autor:innen und Institutionen

  • Department of Urology, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
  • Surgical Intervention Trials Unit, University of Oxford, Oxford, UK.
  • Department of Urology, Wexham Park Hospital, Frimley Health NHS Foundation Trust, Slough, UK.
  • Harold Hopkins Department of Urology, Royal Berkshire Hospital, Royal Berkshire NHS Foundation Trust, Reading, UK.
  • Department of Urology, NHS Lothian, Western General Hospital, Edinburgh, UK.

ORCID-Profile: Richard J Bryant, Tom Leslie, Marc Laniado, Abhishek Sharma, John Withington, Oliver Hulson, Taimur T Shah, Nishant Bedi, Caroline Moore, Hashim U Ahmed, Vicki S Barber, Aimi Hewitt, Clare Calvert, Filipa Landeiro, Jane Wolstenholme, Jo Cook, Catherine R Holt, Jonathan Cook, Ioana R Marian, Daisy Elliott

Förderung

  • Health Technology Assessment Programme

Zitieren

APA

Bryant, R. J., Leslie, T., Laniado, M., Sharma, A., Grey, A., Withington, J., Blick, C., Streeter, E., Kotwal, S., Hulson, O., Cross, W., Good, D. W., Omer, A., Shah, T. T., Bedi, N., Stroman, L., Moore, C., Sooriakumaran, P., Ahmed, H. U., …, & Hamdy, F. C. (2026). The PART randomised trial protocol: Partial Ablation versus Radical Treatment for prostate cancer. BJU International, 138(6), 1013-1024. https://doi.org/10.1111/bju.70448

Vancouver

Bryant RJ, Leslie T, Laniado M, Sharma A, Grey A, Withington J, et al. The PART randomised trial protocol: Partial Ablation versus Radical Treatment for prostate cancer. BJU International. 2026;138(6):1013-1024. doi:10.1111/bju.70448

BibTeX
@article{Bryant2026,
  author = {Bryant, Richard J and Leslie, Tom and Laniado, Marc and Sharma, Abhishek and Grey, Alistair and Withington, John and Blick, Christopher and Streeter, Edward and Kotwal, Sanjeev and Hulson, Oliver and Cross, William and Good, Daniel W and Omer, Altan and Shah, Taimur T and Bedi, Nishant and Stroman, Luke and Moore, Caroline and Sooriakumaran, Prasanna and Ahmed, Hashim U and Brewster, Simon F and Barber, Vicki S and Hewitt, Aimi and Calvert, Clare and Scaife, Jessica and Shepherd, Derek and Landeiro, Filipa and Wolstenholme, Jane and Camilleri, Philip and Verrill, Clare and Lovell, Shelagh and Pirkl, Martin and Gleeson, Fergus and Williams, Roxanne and Cook, Jo and Holt, Catherine R and Hill, Martyn and Cook, Jonathan and Radford, James and Marian, Ioana R and Macpherson, Ruth and Elliott, Daisy and Donovan, Jenny L and Hamdy, Freddie C},
  title = {The PART randomised trial protocol: Partial Ablation versus Radical Treatment for prostate cancer},
  journal = {BJU International},
  year = {2026},
  volume = {138},
  number = {6},
  pages = {1013--1024},
  doi = {10.1111/bju.70448}
}
Kostenlos starten →